4D Molecular Therapeutics Inc (FDMT NASDAQ) stock market data APIs
$4.1523
-0.36(-8.7%)
as of July 1, 2025
Try our APIs with
free plan!
4D Molecular Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V. The company was founded in 2013 and is headquartered in Emeryville, California.
Prev. Close
4.1523
Open
3.7944
High
4.1791
Low
3.6998
52 wk Range
2.235-28.9269
Market Cap
172 M
Shares Outstanding
46 325 K
Revenue
23 000
EPS
-0.86
Beta
2.83
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get 4D Molecular Therapeutics Inc data using free add-ons & libraries
Get 4D Molecular Therapeutics Inc Fundamental Data
4D Molecular Therapeutics Inc Fundamental data includes:
- Net Revenue: 23 000
- EBITDA: -198 795 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: -0.8621
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
4D Molecular Therapeutics Inc News
New
Spotlight On 3 Penny Stocks With Market Caps Under $500M
In the last week, the market has stayed flat, but it is up 11% over the past year, with earnings expected to grow by 14% per annum over the next few years. Though the term 'penny stock' might sound li...
4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden
4D Molecular Therapeutics, Inc. Initial interim landmark data analysis (N=50 at 24 Weeks) will be presented byArshad M. Khanani, M.D., M.A., FASRS, Principal Investigator of the PRISM clinical trial ...
4D Molecular Therapeutics Inc CEO David Kirn Sells 5,696 Shares
On January 23, 2024, David Kirn, CEO of 4D Molecular Therapeutics Inc (NASDAQ:FDMT), sold 5,696 shares of the company's stock, according to a recent SEC Filing. This transaction is part of a series of...
4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease
4D Molecular Therapeutics, Inc. 4D-710 has demonstrated promising, reproducible, CFTR expression significantly above normal levels for seven patients across Cohorts 1 & 2 (1E15-2E15 vg) and durable i...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
